Nursen Cetrez

Solna, AB, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Poor health-related quality of life despite Lupus Low Disease Activity State or Definitions of Remission in systemic lupus erythematosus (SLE) remission in patients with SLE: results from a clinical trial setting.

Poor health-related quality of life despite Lupus Low Disease Activity State or Definitions of Remission in systemic lupus erythematosus (SLE) remission in patients with SLE: results from a clinical trial setting.

Journal: RMD open

Published: June 24, 2025

Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria.

Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria.

Journal: RMD open

Published: January 10, 2025

Lupus nephritis trials network (LNTN) repeat kidney biopsy-based definitions of treatment response: A systematic literature review-based proposal.

Lupus nephritis trials network (LNTN) repeat kidney biopsy-based definitions of treatment response: A systematic literature review-based proposal.

Journal: Autoimmunity reviews

Published: January 10, 2025

Belimumab efficacy in mucocutaneous manifestations of systemic lupus erythematosus: a large post hoc analysis of five phase III clinical trials.

Belimumab efficacy in mucocutaneous manifestations of systemic lupus erythematosus: a large post hoc analysis of five phase III clinical trials.

Journal: Rheumatology (Oxford, England)

Published: December 16, 2024

Unsupervised machine learning identifies distinct SLE patient endotypes with differential response to belimumab.

Unsupervised machine learning identifies distinct SLE patient endotypes with differential response to belimumab.

Journal: Rheumatology (Oxford, England)

Published: December 09, 2024

Predicting EQ-5D full health state in systemic lupus erythematosus using machine learning algorithms.

Predicting EQ-5D full health state in systemic lupus erythematosus using machine learning algorithms.

Journal: Rheumatology advances in practice

Published: July 12, 2024

Neuropsychiatric involvement in systemic lupus erythematosus contributes to organ damage beyond the nervous system: a post-hoc analysis of 5 phase III randomized clinical trials.

Neuropsychiatric involvement in systemic lupus erythematosus contributes to organ damage beyond the nervous system: a post-hoc analysis of 5 phase III randomized clinical trials.

Journal: Rheumatology international

Published: May 21, 2024

Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials.

Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials.

Journal: The Lancet. Rheumatology

Published: December 21, 2023

Patients with NPSLE experience poorer HRQoL and more fatigue than SLE patients with no neuropsychiatric involvement, irrespective of neuropsychiatric activity.

Patients with NPSLE experience poorer HRQoL and more fatigue than SLE patients with no neuropsychiatric involvement, irrespective of neuropsychiatric activity.

Journal: Rheumatology (Oxford, England)

Published: November 28, 2023

Effect of Belimumab on Preventing de novo Renal Lupus Flares.

Effect of Belimumab on Preventing de novo Renal Lupus Flares.

Journal: Kidney international reports

Published: May 06, 2023

Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase III trials of belimumab.

Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase III trials of belimumab.

Journal: Rheumatology (Oxford, England)

Published: February 20, 2023

Showing 1-11 of 11

Last Updated: 09/26/2026